Targeting miR-27 with Antisense Oligonucleotides for Disease Modification in Parkinson’s Disease
Objective: Achieve disease modification in idiopathic Parkinson’s Disease through miR-27 targeting using Antisense Oligonucleotides Background: There are currently no disease-modifying therapies for Parkinson’s Disease (PD).…Faecal Microbiota Transplant for Parkinson’s Disease: a Phase 1 Pilot Study to Establish Safety and Tolerability
Objective: We performed a pilot study looking at the safety and tolerability of Faecal Microbiota Transplantation, its effect on the microbiome, and improvement of symptoms…Possible Sarcopenia and its Association with Physical Activity among Parkinson’s disease Patients
Objective: This study aimed to screen the prevalence of possible sarcopenia and its association with physical activity level in a sample of PD patients. Background:…Continuous Subcutaneous Apomorphine Infusion (CSAI) Improved Confidence When Engaging in Everyday Activities: Survey of InfusON Study Participants
Objective: Evaluate participants' perceptions of their confidence when engaging in daily activities and interpersonal relationships while using CSAI therapy, relative to the period before CSAI…The international validation of the “Stepped Care” toolkit for comprehensive real life clinical care: bridging massive unmet need in care of Parkinson’s disease.
Objective: To conduct a cognitive pretesting of a global, cross-cultural, multicentre (14 countries) Stepped Care clinical toolkit. The questionnaire is completed by the healthcare professional…Improvement in Uninterrupted Good ON Time and Reduction in OFF Periods with CSAI Treatment
Objective: Evaluate the effect of continuous subcutaneous apomorphine infusion (CSAI) on daily periods of OFF time and Good ON time (ON without troublesome dyskinesia) in…Efficacy and Safety of Amantadine in Parkinson’s Disease with Dyskinesia and Motor Fluctuations: A Systematic Review and Meta-Analysis
Objective: To evaluate the efficacy and safety of oral amantadine (AMA) compared to placebo in the treatment of dyskinesia (DYS) and motor fluctuations (MF) in…Comparing the Selected Device-Aided Therapy of Movement Disorder Specialist Team with Patient Selections
Objective: This study aims to compare the decision made by patients and physicians in selecting device-aided therapy (DAT) for advanced Parkinson’s disease (aPD) and to…Transforming Parkinson’s Care in Africa: Establishing the First Ever Support Group for People With Parkinson’s Disease and Their Caregivers in Tanzania.
Objective: To establish a support group for people with Parkinson's disease (PwP) and caregivers in Tanzania as part of the Transforming Parkinson’s Care in Africa…Long-term Safety and Efficacy for Motor Fluctuations and Quality of Life With Foslevodopa/Foscarbidopa in Patients With Advanced Parkinson’s Disease: Interim Results From an Ongoing Open Label Extension
Objective: Evaluate long-term motor symptom control and improvement in quality of life (QoL) with foslevodopa/foscarbidopa (LDp/CDp) compared with baseline (BL) values from the parent study…
- « Previous Page
- 1
- …
- 137
- 138
- 139
- 140
- 141
- …
- 1554
- Next Page »